Aclarion is steadily executing on a confirmed path towards normal of care.
Ten outstanding Key Opinion Chief (KOL) surgeons have formally engaged to accomplice with the corporate to drive market traction and reimbursement.
Firm is poised to report the vital metrics that drive the important thing catalysts of worth creation.
BROOMFIELD, CO, Oct. 02, 2023 (GLOBE NEWSWIRE) — by way of NewMediaWire — Aclarion, Inc., (“Aclarion” or the “Firm”) (Nasdaq: ACON, ACONW), a healthcare know-how firm that’s leveraging biomarkers and proprietary augmented intelligence algorithms to assist physicians determine the situation of power low again ache, introduced as we speak the posting of an up to date Company Overview presentation to the investor part of the Firm web site at Aclarion+Company+Overview+Replace+1+FINAL.pdf to replicate the achievement of key milestones since turning into a publicly traded firm in April of 2022.
Brent Ness, CEO of Aclarion, acknowledged, “Since our Nasdaq IPO, Aclarion has persistently achieved acknowledged catalysts of worth creation to convey our Nociscan know-how to plain of care. We intend to guide a diagnostic transformation in spine care with medical and financial proof. The steps we have now taken in a brief timeframe display that main surgeons and establishments see the worth of our know-how for enhancing outcomes and lowering prices and are partnering to assist drive Nociscan to plain of care.”
A cornerstone of the Firm’s technique is to have interaction main surgeons to make use of Nociscan know-how to non-invasively determine painful discs and display superior surgical outcomes at a decrease financial value. Aclarion now has 11 of the highest spine surgeon leaders on this planet aligned and able to converse on behalf of the efficacy and medical utility of including Nociscan to the analysis of sufferers that suffer from power low again ache. These ten KOLs and one Surgeon Advisory Board chief are dedicated to integrating Nociscan into their medical practices, collaborating within the assortment of medical knowledge, and interesting payers to advocate for protection selections.
“Our listing of KOLs, advisors, and consultants seems extra like that of a multibillion-dollar trade chief than an rising know-how disruptor,” acknowledged Ryan Bond, Chief Technique Officer of Aclarion. “The subsequent step in our march in the direction of normal of care is to activate MRI facilities for every of our surgeon clients. As we announce the onboarding of those MRI’s it will result in elevated scan volumes, the subsequent key catalyst we shall be reporting to buyers. As scan volumes improve and our surgeons display to payers that they’re getting higher medical outcomes at a decrease general value, we anticipate it will end in constructive protection selections from payers. Payer reimbursement is clearly some of the necessary worth creation catalysts for any new medical know-how.”
Proof continues to mount in favor of using Nociscan to find out discogenic ache. The Firm lately introduced the publication of 2-year observe up knowledge on the pivotal Gornet research. Outcomes confirmed that the improved medical outcomes demonstrated at one 12 months for sufferers who underwent surgical procedure on the disc ranges recognized as painful by Nociscan have been sturdy at two years. “You will need to observe that Gornet is a superior outcomes-based research, not only a medical equivalency research to a gold normal diagnostic,” mentioned Bob Eastlack, Orthopedic Surgeon at Scripps Clinic Torrey Pines in La Jolla, CA.
The financial good thing about the superior outcomes related to the Gornet research have been subsequently evaluated by the Middle for Disruptive Musculoskeletal Improvements (CDMI) via The Financial Worth Evaluation of Low Again Ache Research (EVAL). EVAL outcomes demonstrated that Nociscan has the potential to save lots of the U.S. Healthcare System practically half a billion {dollars} yearly and greater than $1,700 per affected person. EVAL was introduced in Could at each the Worldwide Society for the Development of Backbone Surgical procedure (ISASS) assembly and at Backbone Week in Melbourne Australia. The research has been submitted for publication.
The Firm was additionally chosen to take part within the Biomarkers for Evaluating Backbone Remedies (BEST) Trial funded by the NIH. BEST will enroll over 800 sufferers at 12 main educational establishments throughout america, with a subset of 200 sufferers present process superior biomarker profiling that features Nociscan. BEST is a income producing trial the place Nociscan is paid for every scan.
In This fall of 2023, Aclarion will launch its pivotal CLARITY Trial, a nationwide randomized management trial lead by Dr. Nick Theodore MD from Johns Hopkins Medication because the Major Investigator. This multi-site, multi-surgeon research will goal to copy the surgical consequence success of the Gornet research on a nationwide scale.
Jeff Thramann, M.D., Government Chairman of Aclarion, concluded, “The Aclarion workforce is making nice progress executing on the confirmed path for bringing a brand new know-how to plain of care. An unbelievable KOL panel has been established and MRI activations for these surgeons shall be introduced over the approaching months. The workforce will start reporting the next improve in scan volumes in 2024, that are a key close to time period metric for buyers to observe as scan quantity and the anticipated rising physique of favorable medical outcomes knowledge from our KOLs and different surgeon clients will seemingly drive native payers to cowl Nociscan as a primary step in the direction of nationwide reimbursement. A positive protection choice is predicted to be a serious inflection level within the worth of Aclarion.”
For extra details about Aclarion, please go to: Aclarion
About Aclarion, Inc.
Aclarion is a healthcare know-how firm that leverages Magnetic Resonance Spectroscopy (“MRS”), proprietary sign processing strategies, biomarkers, and augmented intelligence algorithms to optimize medical remedies. The Firm is first addressing the power low again ache market with Nociscan, the primary, evidence-supported, SaaS platform to noninvasively assist physicians distinguish between painful and nonpainful discs within the lumbar spine. By a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) knowledge from an MRI machine for every lumbar disc being evaluated. Within the cloud, proprietary sign processing strategies extract and quantify chemical biomarkers demonstrated to be related to disc ache. Biomarker knowledge is entered into proprietary algorithms to point if a disc could also be a supply of ache. When used with different diagnostic instruments, Nociscan offers vital insights into the situation of a affected person’s low again ache, giving physicians readability to optimize therapy methods. For extra info, please go to www.aclarion.com.
Ahead-Wanting Statements
This press launch accommodates forward-looking statements throughout the which means of the Non-public Securities Litigation Reform Act of 1995, Part 27A of the Securities Act of 1933 and Part 21E of the Securities Trade Act of 1934 concerning the Firm’s present expectations about future outcomes, efficiency, prospects and alternatives. Statements that aren’t historic details, reminiscent of “anticipates,” “believes” and “expects” or related expressions, are forward-looking statements. These forward-looking statements are primarily based on the present plans and expectations of administration and are topic to various uncertainties and dangers that would considerably have an effect on the Firm’s present plans and expectations, in addition to future outcomes of operations and monetary situation. These and different dangers and uncertainties are mentioned extra absolutely in our filings with the Securities and Trade Fee. Readers are inspired to assessment the part titled “Danger Elements” within the Firm’s Prospectus dated April 21, 2022, as filed with the Securities and Trade Fee on April 25, 2022 below Rule 424(b)(4), in addition to different disclosures contained within the Prospectus and subsequent filings made with the Securities and Trade Fee. Ahead-looking statements contained on this announcement are made as of this date and the Firm undertakes no obligation to publicly replace or revise any forward-looking statements, whether or not because of new info, future occasions or in any other case.
Investor Contacts:
Kirin M. Smith
PCG Advisory, Inc.
646.823.8656
ksmith@pcgadvisory.com
Media Contacts:
Jodi Lamberti
SPRIG Consulting
612.812.7477
jodi@sprigconsulting.com
Discussion about this post